Blog

FDA 510(k) Modifications – Inclusion of Non-Triggering Change Details

March 3, 2023

FDA 510(k) Modifications – Inclusion of Non-Triggering Change Details

 

If multiple changes have been made to the subject device since the prior 510(k), but where only one/some of those changes trigger(s) the need for a new 510(k), and if the aggregate of changes isn’t what’s triggering the need for the new 510(k), then you “should” (meaning this isn’t a requirement) in the 510(k) simply identify and describe the nature of the changes that don’t require submission of the new 510(k).   Indeed, the actual mandate regarding the non-triggering changes is for you to detail those aspects internally in accordance with the QS regulations.  In other words, the developmental documentation and data (e.g., test results/reports, etc.) associated with the non-triggering aspects should definitely NOT be included in the 510(k).  Instead, keep the substance of the 510(k) focused on those aspects that triggered the 510(k) for the changed device; specifically, those changes that can “significantly affect safety and effectiveness”.  I explain further below.

 

A 510(k) is a statutory creature that has a very specific purpose; namely, to demonstrate the statutory substantial equivalence of the subject device in comparison to a predicate device.  Accordingly, I generally advise and practice that the substance of the 510(k) needs to be strictly and succinctly focused on that statutory substantial equivalence assertion.  My clients will tell you my mantra that every word, sentence, and component of the 510(k) needs to be strategically written so as to specifically address the substantial equivalence statute and regulations.  Any information and data that doesn’t directly relate to this substantial equivalence exercise only convolutes the aim of the 510(k), and can easily confuse and frustrate the FDA reviewer.  This is because the inclusion of data not related to the substantial equivalence assertion signals to the FDA that the sponsor believes that those aspects are in fact germane to the substantial equivalence effort. In other words, that those attributes could significantly affect safety and effectiveness. Don’t lead FDA down that path unless it is truly necessary from the standpoint of the statutory intent of a section 510(k) notification.

 

If disclosing a non-triggering change(s) at all, then I prefer to put each change’s explanation in the subsection of the 510(k) corresponding to the nature of the particular non-triggering change.  For example, if a non-triggering change has been made in the labeling, then I disclose that in the labeling subsection.  If a non-triggering change was made regarding form/fit/function, then I disclose that in the device description (among other corresponding subsections as appropriate), and so on.

Regulatory is Part of the Design and Design Team: Part 2

March 2, 2023

Regulatory is Part of the Design and Design Team: Part 2

 

Here are a few more practical examples generally demonstrating that Regulatory can’t be separated from the design team.

 

For example, if a Regulatory staffer compiled the GSPR matrix or an FDA 510(k), then that unfortunately means that staffer wrote regulatory design outputs.  For example, ISO TC/210 includes as design outputs, “documentation for submission to the regulatory authorities“.  This is because ISO 13485 (and FDA) have very deliberate and distinct requirements for regulatory inputs, outputs, etc., as distinguished from the subject device’s functional and performance requirements.  Be sure not to equate the regulatory inputs/outputs with the device’s functional/performance requirements that might be embedded or referenced within the regulatory outputs.  Again, for these reasons, I don’t expect that a notified body, an ISO registrar, or FDA would buy the assertion that the team’s regulatory contributor isn’t part of the design team, nor do I expect these authorities to accept attempts to have said regulatory contributor be the independent reviewer or “other specialist personnel” regarding those regulatory inputs/outputs, verification, etc. Consequently, if one fought the regulatory authority in such instances, then I expect that you could not only lose that battle, but also in the process damage the organization’s relationship with the regulatory authority, and thus the organization’s premarket authorization efforts.  There are certainly proper times to push back on a regulatory authority; but this doesn’t seem to be one of them.

 

I also think it’s a losing battle to argue that a primary author/contributor of a critical part(s) of the device specification and/or IFU, such as adding (i.e., writing) an indication for use consistent with the predicate, isn’t a design team member.

 

Similarly, if a person signed off on and/or “completed” process, packaging, and sterilization validations, then again, then I expect it will be a losing battle to argue that such person isn’t a design team member.

 

Likewise, if a team member reviews the design verification/validation protocols and reports for regulatory compliance (meaning that such member is participating in design verification/validation), then I view it as a stretch (or worse) to assert that such person isn’t part of the design team.

 

It’s also important to be mindful that ISO TC/210 and FDA expect the design team and its members’ roles to be very clearly defined (i.e., in the design plan).  FDA says that, “The importance of defining responsibilities with clarity and without ambiguity should be recognized.”  ISO TC/210 says, “It needs to be clear who has responsibility and authority for design and development. Generally, as different groups or functions within your organization are involved in design and development, clear and effective communication with distinct assignment of responsibilities across your organization is important….The design and development plan should identify the review, verification and validation methods to be used, including who is to carry them out…” [emphasis added].  This alludes to the pitfalls of arguing against a regulatory authority’s inclusion of the cited personnel contributions as being part of the design team.

 

I tend to reflexively agree with some concerns/objections about inclusion of the QMS procedures as design documents requiring design team member attendance.  Yet if a regulatory authority wanted to really flex its muscles when push comes to shove, then I expect that it could also sustain an argument in some cases that authoring or release of QMS procedures to assure regulatory compliance could be part of the aforesaid regulatory design outputs (see my foregoing regulatory inputs/outputs explanations).  For example, remember that conformity with the EU MDR requires creation of QMS procedures according to the EU MDR.

Regulatory is Part of the Design and Design Team: Part 1

March 2, 2023

Regulatory is Part of the Design and Design Team: Part 1

 

ISO 13485 demands that regulatory requirements be included in the required design inputs and outputs along with the corresponding verification (and maybe also validation depending on how a client approaches it). Consequently, the person who authored those regulatory design inputs, outputs, and/or verifications can’t be used as an independent reviewer of those design elements.

 

Although ISO 13485 doesn’t state a requirement for an independent reviewer, clients’ SOPs often do.  This is typically for addressing other jurisdictional requirements calling for an independent reviewer like those of the FDA.  If the SOP demands an independent reviewer and defines it in the usual way (i.e., as someone who doesn’t have direct responsibility for the stage/artifact being reviewed), then the team’s regulatory member who authored the regulatory inputs/outputs/verification is disqualified from being the independent reviewer of those artifacts.  Accordingly, a Notified Body (NB) nonconformity (NC) cited on this basis is in fact a valid NC.  In such a case, it can be necessary for an outside consultant/contract reviewer to be deployed for fulfilling the independent reviewer role.

 

On the topic of asserting that the regulatory team member is a part of the “project” team rather than the design team, the aforesaid ISO 13485 (and FDA) requirement for specific regulatory design inputs, outputs, verification, etc., precludes arguing that the person who authored those regulatory artifacts is a “project” team member rather than a design team member.  Such an argument will not hold up under scrutiny, as that notion conflicts with ISO 13485’s (and FDA’s) requirement for integration of regulatory requirements into the design requirements.

 

The person who authored the regulatory artifacts also cannot function as “other specialist personnel”.  This is because ISO 13485 requires that the design review team shall first include representatives of the functions concerned (i.e., the regulatory team member who authored the regulatory artifacts) as well as other specialist personnel.

 

In light of all this, I think one would be unsuccessful trying to argue against an NC asserting that Regulatory needs to be considered part of the design team rather than an independent reviewer, other specialist personnel, or just a “project” team member.  Instead, it would be better to find a sustainable solution(s) that will be within the boundaries I’ve laid out above.  For example, if a client has already hired three outside workers, then hiring another one on a limited basis for supporting design reviews should be within reason in my opinion.

FDA 510(k) Change Strategy: Reprocessing-Focused

February 28, 2023

FDA 510(k) Change Strategy: Reprocessing-Focused

 

If the only thing that has changed is the reprocessing process, then the substance of the new 510(k) can just be focused on the aspects that changed.  In other words, no need to restate the device description, software contents, etc., etc., that aren’t affected by the change.  However, each of those various unaffected elements still DOES need to be attended to in their respective sections of the 510(k); yet only by referring FDA to the corresponding details in the prior 510(k) and stating that those elements are unchanged and unaffected for the current subject device.

EU MDR PMCF Plan is Needed for Legacy Devices

February 28, 2023

EU MDR PMCF Plan is Needed for Legacy Devices

 

In order for an EU MDR Article 120 “legacy” device (as defined in MDCG 2021-25) MDD certificate to remain valid, certain conditions upon which issuance of that legacy MDD certificate was based shall be maintained regardless of whether devices have yet been placed on the market.  For example, even if the legacy device was never before placed on the market, Annex III still requires a PMS Plan and, where not eligible for the EU MDR’s general PMCF waiver opportunity, a PMCF Plan, as a condition for maintenance of the validity of the legacy MDD certificate.  In other words, said PMCF Plan (and overarching PMS Plan) is generally required to be drawn up and ready for execution as a condition of maintaining the validity of the legacy MDD certificate.  Again this remains the case even if the legacy device hasn’t yet been placed on the market.

 

Note also that it is my understanding that, as a general rule, the planned/required PSUR shall also be drawn up at the required time.  If, at such time, no devices were yet placed on the market, then the PSUR simply states in the corresponding sections that there are yet no PMS / PMCF data collected for the marketing of the subject device because no subject devices have yet been placed on the market.

 

However, be aware that part of the PMS plan upon which the legacy MDD certificate is contingent requires collection and analysis of PMS data not just on the marketing of the subject device.  Specifically, the PMS plan also requires collection and analysis of data from specialist or technical literature, databases and/or registers, and publicly available information about similar medical devices.  Accordingly, be sure you have suitably addressed those required PMS aspects even if you haven’t yet marketed the subject device.

What Changes are Allowed for EU MDR Article 120 Legacy Devices?

February 24, 2023

What Changes are Allowed for EU MDR Article 120 Legacy Devices?

 

In general, from purely a legislative EU MDR / MDD perspective, if an EU MDR Article 120(2/3) MDD-certified transitional device has, “…no significant changes in the design and intended purpose…”, then it can be placed on the market or put into service under the MDD certificate until the EU MDR Article 120’s corresponding sunset deadlines.  This means that changes are in fact allowed to be made to the Article 120 transitional device, and that the changed device can in fact be placed on the market, as long the change and the composite of multiple changes made since MDD certification, doesn’t exceed the Article 120 limits (no significant change in the design or intended purpose).

 

However, sometimes your contract with your Notified Body (NB) might deviate with the pure legislative intentions of Article 120.  So be sure to check your NB contract to see what obligations it demands.  If that contract requires formal NB notification and/or approval of changes that don’t align with the Article 120 provisions, then you would be legally bound by that contract and would thus need to lobby the NB for a contract revision or concession.

Health Canada Class IV Device Licence Amendment and Fee Forms

February 24, 2023

Health Canada Class IV Device Licence Amendment and Fee Forms

 

For a Health Canada Class IV medical device licence amendment, there are generally two types of forms needed:

 

  1. Class IV Medical Device Licence Amendent Application Form

  2. Medical Device Application Fee Form

 

On the Application Form, we can bundle multiple types of changes (e.g., classification, manufacturing, design/performance, labelling, materials, etc., etc.) by checking all of the applicable boxes and  including the corresponding supporting documentation.

 

But the Fee Form and its drop-down menu only allows us to select one type of amendment and calculate the fee for that particular aspect.  But since the applicable fee regulations (e.g., SOR/2019-124) are intended for Health Canada to collect all fees applicable depending on the full scope of the amendment, then I complete a separate fee form for each type of triggering amendment.

 

So the overall application package would include one Application Form supported by the fee form (or forms) needed to cover the various fees for all of the triggering billable changes in the amendment.

 

In the end, Health Canada will in due course calculate and, as needed, adjust, the ultimate fee invoice accordingly based on the scope of the amendment.

What if I Add an Expiration Date for Risk Reduction?

February 24, 2023

What if I Add an Expiration Date for Risk Reduction?

 

If, to reduce risk, you are adding an expiration date to a medical device model for which previously-marketed units do not have such an expiration date, then, generally speaking, the governing regulatory authorities will reflexively suspect/assert that a recall might be needed.  Accordingly, such a preventive measure needs to be properly put through a recall trigger assessment process to see if your risk reduction actions meet the risk reduction triggers of applicable recall statutes/regulations/ordinances, etc.  If you aren’t adept at such recall deliberations, then you should consider getting expert assistance.

Real-Time or Accelerated Aging?

February 22, 2023

Real-Time or Accelerated Aging?

 

As a general rule in the medical device sector, accelerated aging data is expected to be ultimately backed up with real-time data.  Consequently, we still generally need to have real-time data to support whatever (let’s say, a 6-year) shelf life we are targeting.  If for example we have a 4-year real-time aging study but 6 years worth of accelerated aging, then we can label with a 6-year expiration date in the interim until 6 years of real-time data are completed.